GILD has all the patient experience.
The other point is EXAS has had several years to improve the science. I for one would not want to have a false negative on an EXAS test when my insurance would pay for a more expensive colonoscopy.
will hold shares . At this level very little risk.
new, improved testing that reduces false outcomes. Either way, stock goes up.
That's $104 at a PE of 8. Most likely there will be an avalanche effect of huge numbers of prescriptions in U.S. Europe, Japan combined., together with share buyback, offsetting any drop in price per script.
Brain cancer is not curable folks.
DIY is the American way, all he way.
to get NDA from FDA by 2019/2020. Check it out.
and insurance companies to approve. I can see this device being used with other break-thru therapies.
If the answer is YES, then longs will do well.
at 95 the downside is very limited, and the risk/reward is therefore in your favor..
Financing is already in place. Risk/reward looks good here.
Solid scripts, pricing, Euro, Japan, share buyback all positives.
Load up and save for better days
No other biotech with solid earnings, low PE, dividend, big moat.
This will blow over.e